what are we doing?
Story
Since millions of years ago fitohormones (e.g. auxins) have been reprograming TIR1 E3 ubiquitin ligase to change its ubiquitylation and degradation specificity.
Captor Therapeutics
who are we?
About us
Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".
Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.
-
1999
Kenten J. and Roberts S. filed a patent application for compounds activating ubiquitination of a target protein. An idea of Ubiquitin Proteasome System modulation emerged.
-
2001
Proof of Principle - targeted protein degradation with peptidic bifunctional moleculewas reported (Sakamoto K. et al., PNAS).
-
2004
Nobel Prize in Chemistry was awarded for the discovery of ubiquitin-mediated protein degradation (Aaron Ciechanover, Avram Hershko and Irwin Rose).
-
2008
First small molecule bifunctional degrader was reported (Smith A. et al., Bioorg. Med. Chem. Lett.).
-
2010
Cereblon E3 ubiquitin ligase complex was identified as thalidomide’s target. The discovery fuelled progress in a Targeted Protein Degradation technology (Ito T. et al., Science).
-
2017what's next?
Optigrade™ platform at Captor Therapeutics – degraders inspired by nature.
what are we doing?
Our approach
At Captor Therapeutics, we cover all aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade™ Targeted Protein Degradation (TPD) platform allows for the sustainable creation of new drugs.
Our integrated approach combines competencies in medicinal chemistry, molecular modelling, protein sciences, biophysics, and pharmacology. 1,100 m2 of laboratory space equipped with state-of-the-art machinery allows for full control of the drug development process and its dynamics.
Supported by over 44 million EUR from European grants and private investors, we are currently working on several projects aiming at:
(1) the development of first-in-class therapeutics for oncological and autoimmune indications and
(2) the evolution of our Optigrade™ platform to allow the creation of second and third generation degrader drugs with enhanced efficacy, selectivity and pharmaceutical properties.
want to be one of us?
Careers
Click the button below to expand panel with job offers to find an offer that interests you and submit an application to become one of us!
stay in touch
Contact
Captor Therapeutics Inc
ul. Duńska 11
54-427 Wrocław, Poland
Captor Therapeutics GmbH
Hegenheimermattweg 167A
4123 Allschwil, Switzerland
- Poland
- Switzerland